Predicting Medication Response in Obsessive Compulsive Disorder

Status Completed

Clinical Trial Summary

In this study, the investigators hope to study a number of variables the investigators believe may help us predict why some people respond better to some medications than others. Participants will be randomly assigned to receive one of two typical medications for OCD, clomipramine or escitalopram. Individuals who would like to participate but who have previously tried one or both of these medications may instead take a newer drug, duloxetine, and undergo the identical procedures. The factors the investigators will be studying include demographics (i.e. age, gender, age of onset of OCD), genetic markers (such as variants in genes involved in breaking down drugs in the liver (cytochrome P450 system), and genes involved in several brain chemical systems, such as serotonin), the dimensions of OCD symptoms (i.e. checking, washing, and hoarding) and cortical inhibition. Cortical inhibition will be measured transcranial magnetic stimulation and is being studied because deficits in this process may be important in the development of OCD. The investigators hypothesize that certain pretreatment clinical characteristics will correlate with poor treatment response including earlier age of onset, longer duration of illness, increased YBOCS severity and presence of significant hoarding symptoms. The investigators expect that increasing degree of deficit in CI pre-treatment will predict poor treatment response, but that increase in CI from pre- to post-treatment will correlate with a positive treatment response. Differences in genetic marker status for cytochrome P450 genes will correlate with tolerability and/or response, as well as differences in genetic marker status in SLC1A1, GRIN2B, 5HT1B and 5HT2A will correlate with response.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01404871
Study type	Interventional
Source	Sunnybrook Health Sciences Centre
Contact
Status	Completed
Phase	N/A
Start date	April 2009
Completion date	December 2011

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04631042` - Developing Brain, Impulsivity and Compulsivity
Completed	`NCT02855580` - Integrating Pharmacogenomic Testing Into a Child Psychiatry Clinic
Completed	`NCT02229903` - An Evaluation of the Safety and Efficacy of the dTMS Treatment for OCD	N/A
Completed	`NCT02202915` - CBT for Pediatric OCD: Community Training Pilot	N/A
Completed	`NCT01794156` - Evaluation of a Cognitive Therapy (Inference-based-therapy) for the Treatment of Obsessional Compulsive Disorder	N/A
Completed	`NCT02089984` - Web Based Therapist Training on Cognitive Behavior Therapy for Anxiety Disorders	N/A
Completed	`NCT01348529` - Internet Cognitive Behavior Therapy (CBT) for Obsessive Compulsive Disorder (OCD)	N/A
Recruiting	`NCT00965211` - Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Safety and Feasibility Study for the Treatment of Tourette Syndrome	N/A
Not yet recruiting	`NCT00743834` - Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD)	Phase 4
Completed	`NCT01172873` - D-Cycloserine Augmentation to CBT With Exposure and Response Prevention in Adults and Adolescents With OCD	N/A
Completed	`NCT00723060` - Comparison of Effects Between Conventional Dose and High Dose Escitalopram on Clinical Improvement in Patients With Obsessive-compulsive Disorder	Phase 4
Completed	`NCT02421315` - Overlapping Neural Circuits in Pediatric OCD	N/A
Completed	`NCT02194075` - Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder	Phase 4
Completed	`NCT01981317` - Stepped Care Cognitive Behavioral Therapy for Pediatric Obsessive Compulsive Disorder	N/A
Completed	`NCT01686087` - Attaining and Maintaining Wellness in Obsessive-compulsive Disorder	N/A
Completed	`NCT01331876` - Modification of Cerebral Activity of Obsessive Compulsive Disorder (OCD) Patients During Cognitive and Behavioral Therapy	N/A
Terminated	`NCT00997087` - A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder	Phase 2
Completed	`NCT00533806` - Comparing the Effectiveness of Two Family-based Therapies in Treating Young Children With Obsessive-Compulsive Disorder	Phase 3
Completed	`NCT00517244` - Evaluating Parenting Styles and Child Temperament Associated With Child Anxiety Disorders	N/A
Completed	`NCT00169377` - Subthalamic Nucleus (STN) Stimulation and Obsessive-Compulsive Disorder (OCD)	Phase 1/Phase 2